Literature DB >> 15973451

Simultaneous detection of NPM1 and FLT3-ITD mutations by capillary electrophoresis in acute myeloid leukemia.

N I Noguera1, E Ammatuna, D Zangrilli, S Lavorgna, M Divona, F Buccisano, S Amadori, C Mecucci, B Falini, F Lo-Coco.   

Abstract

Mutations in the Nucleophosmin (NPM1) gene have been recently described to occur in about one-third of acute myeloid leukemias (AML) and represent the most frequent genetic alteration currently known in this subset. These mutations generate an elongated NPM1 protein that localizes aberrantly in the cytoplasm. In analogy with Flt3 alterations, NPM1 mutations are mostly detectable in AML with normal karyotype and their recognition may be relevant to identify distinct response to treatment. Hence, in addition to conventional karyotyping and RT-PCR of fusion genes, combined analysis of both Flt3 and NPM1 mutations will be increasingly relevant in the genetic diagnosis work-up of AML. We developed a multiplex RT-PCR assay followed by capillary electrophoresis to simultaneously analyze NPM1 and Flt3 gene alterations (NFmPCR assay). The assay was validated in leukemic cell RNAs extracted from 38 AML patients, which had been previously characterized for Flt3 status by conventional RT-PCR. Direct sequencing of NPM1 RT-PCR products was carried out in 15 cases to verify results obtained by capillary electrophoresis. Both NPM1 sequencing and conventional RT-PCR Flt3 results showed 100% concordance with the results of the NFmPCR assay. We suggest that this assay may be introduced in routine analysis of genetic alterations in AML. Leukemia (2005) 19, 1479-1482.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15973451     DOI: 10.1038/sj.leu.2403846

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  26 in total

1.  NPM1 gene deletions in myelodysplastic syndromes with 5q- and complex karyotype.

Authors:  Emanuele Ammatuna; Paola Panetta; Xabier Agirre; Tiziana Ottone; Serena Lavorgna; Maria José Calasanz; Francesco Lo-Coco
Journal:  Haematologica       Date:  2011-03-10       Impact factor: 9.941

2.  Comparing i.v. BU dose intensity between two regimens (FB2 vs FB4) for allogeneic HCT for AML in CR1: a report from the Acute Leukemia Working Party of EBMT.

Authors:  M A Kharfan-Dabaja; M Labopin; A Bazarbachi; R M Hamladji; D Blaise; G Socié; B Lioure; A Bermudez; L Lopez-Corral; R Or; W Arcese; N Fegueux; A Nagler; M Mohty
Journal:  Bone Marrow Transplant       Date:  2014-06-30       Impact factor: 5.483

3.  Genetic abnormalities in acute myelogenous leukemia with normal cytogenetics.

Authors:  David Wald; Johanna M Vermaat; Gil Peleg; William Tse
Journal:  Curr Hematol Malig Rep       Date:  2008-04       Impact factor: 3.952

4.  Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial.

Authors:  Maria Teresa Voso; Richard A Larson; Dan Jones; Guido Marcucci; Thomas Prior; Jürgen Krauter; Michael Heuser; Serena Lavorgna; Josep Nomdedeu; Susan M Geyer; Alison Walker; Andrew H Wei; Jorge Sierra; Miguel A Sanz; Joseph M Brandwein; Theo M de Witte; Joop H Jansen; Dietger Niederwieser; Frederick R Appelbaum; Bruno C Medeiros; Martin S Tallman; Richard F Schlenk; Arnold Ganser; Sergio Amadori; Yuan Cheng; YinMiao Chen; Celine Pallaud; Ling Du; Alfonso Piciocchi; Gerhard Ehninger; John Byrd; Christian Thiede; Konstanze Döhner; Richard M Stone; Hartmut Döhner; Clara D Bloomfield; Francesco Lo-Coco
Journal:  Blood Adv       Date:  2020-10-13

Review 5.  Molecular prognostic markers for adult acute myeloid leukemia with normal cytogenetics.

Authors:  Tara K Gregory; David Wald; Yichu Chen; Johanna M Vermaat; Yin Xiong; William Tse
Journal:  J Hematol Oncol       Date:  2009-06-02       Impact factor: 17.388

6.  A new DNA-based test for detection of nucleophosmin exon 12 mutations by capillary electrophoresis.

Authors:  Philippe Szankasi; Mohamed Jama; David W Bahler
Journal:  J Mol Diagn       Date:  2008-04-10       Impact factor: 5.568

7.  Nucleophosmin (NPM1) mutations in acute myeloid leukemia: an ongoing (cytoplasmic) tale of dueling mutations and duality of molecular genetic testing methodologies.

Authors:  Gerald Wertheim; Adam Bagg
Journal:  J Mol Diagn       Date:  2008-04-10       Impact factor: 5.568

8.  An allele-specific rt-PCR assay to detect type A mutation of the nucleophosmin-1 gene in acute myeloid leukemia.

Authors:  Tiziana Ottone; Emanuele Ammatuna; Serena Lavorgna; Nélida I Noguera; Francesco Buccisano; Adriano Venditti; Laura Giannì; Massimiliano Postorino; Giorgio Federici; Sergio Amadori; Francesco Lo-Coco
Journal:  J Mol Diagn       Date:  2008-04-10       Impact factor: 5.568

9.  Early peripheral clearance of leukemia-associated immunophenotypes in AML: centralized analysis of a randomized trial.

Authors:  Giacomo Gianfaldoni; Francesco Mannelli; Tamara Intermesoli; Sara Bencini; Damiano Giupponi; Giorgio Farina; Ilaria Cutini; Maria Ida Bonetti; Arianna Masciulli; Ernesta Audisio; Dario Ferrero; Chiara Pavoni; Anna Maria Scattolin; Alberto Bosi; Alessandro Rambaldi; Renato Bassan
Journal:  Blood Adv       Date:  2020-01-28

10.  Clinical Validation and Implementation of a Measurable Residual Disease Assay for NPM1 in Acute Myeloid Leukemia by Error-Corrected Next-Generation Sequencing.

Authors:  Lauren L Ritterhouse; Megan Parilla; Chao Jie Zhen; Michelle N Wurst; Rutika Puranik; Candace M Henderson; Neda Z Joudeh; Madeline J Hartley; Rishikesh Haridas; Pankhuri Wanjari; Larissa V Furtado; Sabah Kadri; Jeremy P Segal
Journal:  Mol Diagn Ther       Date:  2019-12       Impact factor: 4.074

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.